Redox regulation, NF-κB, and atrial fibrillation

Antioxidants and Redox Signaling

Volumn 11, Issue 9, 2009, Pages 2265-2277

  Gao, Ge ^a   Dudley Jr , Samuel C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CHANNEL; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; XANTHINE OXIDASE;

ARTIFICIAL HEART PACEMAKER; BRUGADA SYNDROME; DISEASE PREDISPOSITION; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION PROFILING; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HUMAN; LIPID PEROXIDATION; LONG QT SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION;

ATRIAL FIBRILLATION; GENE EXPRESSION REGULATION; HUMANS; NF-KAPPA B; OXIDATION-REDUCTION; TRANSCRIPTION, GENETIC;

EID: 68949210666     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2595     Document Type: Review

References (119)

1. Akar FG, Spragg DD, Tunin RS, Kass DA, and Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 95: 717-725, 2004.
2. Allessie M, Ausma J, and Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54: 230-246, 2002.
3. Alsheikh-Ali AA, Wang PJ, Rand W, Konstam MA, Homoud MK, Link MS, Estes NA, III, Salem DN, and Al Ahmad AM. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 147: 1061-1065, 2004.
4. Blitzer M, Costeas C, Kassotis J, and Reiffel JA. Rhythm management in atrial fibrillation-with a primary emphasis on pharmacological therapy: Part 1. Pacing Clin Electrophysiol 21: 590-602, 1998.
5. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, and Dhein S. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42: 1785-1792, 2003.
6. Bowie A and O'Neill LA. Oxidative stress and nuclear factor-kB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59: 13-23, 2000.
7. Brasier ARThe NF-κB regulatory network. Cardiovasc Toxicol 6: 111-130, 2006.
8. Brundel BJ, Henning RH, Kampinga HH, van Gelder IC, and Crijns HJ. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 54: 315-324, 2002.
9. Brutsaert DLCardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 83: 59-115, 2003.
10. Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, and Frangogiannis NG. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173: 57-67, 2008.
11. Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, Wang XL, Lee HC, Caplice NM, and Packer DL. Impact of transforming growth factor-β1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation 113: 2485-2494, 2006.
12. Burstein B and Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51: 802-809, 2008.
13. Cai H, Li Z, Dikalov S, Holland SM, Hwang J, Jo H, Dudley SC, Jr., and Harrison DG. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem 277: 48311-48317, 2002.
14. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC, Jr., Harrison DG, and Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106: 2854-2858, 2002.
15. Campbell KP, Lipshutz GM, and Denney GH. Direct photoaffinity labeling of the high affinity nitrendipine-binding site in subcellular membrane fractions isolated from canine myocardium. J Biol Chem 259: 5384-5387, 1984.
16. 3-I receptor mRNA expression in patients with atrial fibrillation. Chin Med J 115: 664-667, 2002.
17. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, and Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89: E32-E38, 2001.
18. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, and Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8: 691-728, 2006.
19. Charital YM, Haasteren GV, Massiha A, Schlegel W, and Fujita T. A functional NF-κB enhancer element in the first intron contributes to the control of c-fos transcription. Gene 430: 116-122, 2009.
20. Chen CL, Lin JL, Lai LP, Pan CH, Huang SK, and Lin CS. Altered expression of FHL1, CARP, TSC-22 and P311 provide insights into complex transcriptional regulation in pacing-induced atrial fibrillation. Biochim Biophys Acta 1772: 317-329, 2007.
21. 2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation 110: 2651-2657, 2004.
22. Coleman TA, Kunsch C, Maher M, Ruben SM, and Rosen CA. Acquisition of NFκB1-selective DNA binding by substitution of four amino acid residues from NFkB1 into RelA. Mol Cell Biol 13: 3850-3859, 1993.
23. d'Avila A and Ruskin JN. Nonpharmacologic strategies: The evolving story of ablation and hybrid therapy. Am J Cardiol 102: 20H-24H, 2008.
24. Dai SM, Zhang S, Chu JM, Guo YH, Chen KP, and Yao S. Blockade of renin-angiotensin system: Aa supplementary treatment for circumferential pulmonary vein isolation in treating persistent atrial fibrillation. Med Hypotheses 69: 767-772, 2007.
25. Danik S, Neuzil P, d'Avila A, Malchano ZJ, Kralovec S, Ruskin JN, and Reddy VY. Evaluation of catheter ablation of periatrial ganglionic plexi in patients with atrial fibrillation. Am J Cardiol 102: 578-583, 2008.
26. Dilaveris P, Giannopoulos G, Synetos A, and Stefanadis C. The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Hematol Disord 5: 387-403, 2005.
27. Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, Stagliano N, Fairchild-Huntress V, Xu J, Lorenz JN, Kadambi V, Berul CI, and Breitbart RE. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 35: 1043-1053, 2003.
28. Dudley SC, Jr., Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, and Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112: 1266-1273, 2005.
29. Dzau VJTissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153: 937-942, 1993.
30. Gao G, Shang LL, Zhou A, Jiao Z, Gaconnet G, and Dudley SC, Jr. The possible mechanism of acquired sodium channel mRNA splicing variants with human heart failure. Circulation 118: S873, 2008.
31. Gassanov N, Brandt MC, Michels G, Lindner M, Er F, and Hoppe UC. Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: Potential role for early remodeling in atrial fibrillation. Cell Calcium 39: 175-186, 2006.
32. Gavras I and Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens 13: 512-517, 2000.
33. Genolet R, Wahli W, and Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 3: 361-375, 2004.
34. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, and Oursler MJ. TGF-β coordinately activates TAK1/MEK/AKT/NFκB and SMAD pathways to promote osteoclast survival. Exp Cell Res 314: 2725-2738, 2008.
35. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwohner M, Strugala D, Pfeiffenberger J, Rohl FW, Huth C, Ebert MP, Klein HU, and Rocken C. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117: 732-742, 2008.
36. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, and Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35: 1669-1677, 2000.
37. 2+ channel in persistent atrial fibrillation in humans. Z Kardiol 89 Suppl 4: IV23-IV29, 2000.
38. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
39. Grove M and Plumb M. C/EBP, NF-κB, and c-Ets family members and transcriptional regulation of the cell-specific and inducible macrophage inflammatory protein 1a immediate-early gene. Mol Cell Biol 13: 5276-5289, 1993.
40. Hall G, Hasday JD, and Rogers TB. Regulating the regulator: NF-κB signaling in heart. J Mol Cell Cardiol 41: 580-591, 2006.
41. Herron BJ, Rao C, Liu S, Laprade L, Richardson JA, Olivieri E, Semsarian C, Millar SE, Stubbs L, and Beier DR. A mutation in NFκB interacting protein 1 results in cardiomyopathy and abnormal skin development in wa3 mice. Hum Mol Genet 14: 667-677, 2005.
42. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, and Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41: 2164-2171, 2003.
43. Iglarz M, Touyz RM, Viel EC, Amiri F, and Schiffrin EL. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system. Am J Hypertens 17: 597-603, 2004.
44. Jamaluddin M, Wang S, Boldogh I, Tian B, and Brasier AR. TNF-α-induced NF-κB/RelA Ser(276) phosphorylation and enhanceosome formation is mediated by an ROS-dependent PKAc pathway. Cell Signal 19: 1419-1433, 2007.
45. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L. IL-1beta-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117, 2003.
46. Jung YJ, Isaacs JS, Lee S, Trepel J, and Neckers L. Microtubule disruption utilizes an NFκ B-dependent pathway to stabilize HIF-1α protein. J Biol Chem 278: 7445-7452, 2003.
47. Kasi VS, Xiao HD, Shang LL, Iravanian S, Langberg J, Witham EA, Jiao Z, Gallego CJ, Bernstein KE, and Dudley SC, Jr. Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation. Am J Physiol Heart Circ Physiol 293: H182-H192, 2007.
48. K1) arising from KCNJ2 mutation. A simulation study. Prog Biophys Mol Biol 98: 186-197, 2008.
49. Kim YH, Lim DS, Lee JH, Shim WJ, Ro YM, Park GH, Becker KG, Cho-Chung YS, and Kim MK. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 35: 336-349, 2003.
50. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, and Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 97: 629-636, 2005.
51. Kleber AG and Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 84: 431-488, 2004.
52. Korantzopoulos P, Kolettis TM, Galaris D, and Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 115: 135-143, 2007.
53. Krijnen PA, Meischl C, Hack CE, Meijer CJ, Visser CA, Roos D, and Niessen HW. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 56: 194-199, 2003.
54. Kubota I, Han X, Opel DJ, Zhao YY, Baliga R, Huang P, Fishman MC, Shannon RP, Michel T, and Kelly RA. Increased susceptibility to development of triggered activity in myocytes from mice with targeted disruption of endothelial nitric oxide synthase. J Mol Cell Cardiol 32: 1239-1248, 2000.
55. Kunsch C, Ruben SM, and Rosen CA. Selection of optimal κB/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol Cell Biol 12: 4412-4421, 1992.
56. 2+-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol 33: 1231-1237, 1999.
57. Lai LP, Su MJ, Lin JL, Lin FY, Tsai CH, Chen YS, Tseng YZ, Lien WP, and Huang SK. Changes in the mRNA levels of delayed rectifier potassium channels in human atrial fibrillation. Cardiology 92: 248-255, 1999.
58. Lakshminarayan K, Anderson DC, Herzog CA, and Qureshi AI. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist 14: 143-150, 2008.
59. Lamirault G, Gaborit N, Le MN, Chevalier C, Lande G, Demolombe S, Escande D, Nattel S, Leger JJ, and Steenman M. Gene expression profile associated with chronic atrial fibrillation and underlying valvular heart disease in man. J Mol Cell Cardiol 40: 173-184, 2006.
60. Lebeche D, Kaprielian R, and Hajjar R. Modulation of action potential duration on myocyte hypertrophic pathways. J Mol Cell Cardiol 40: 725-735, 2006.
61. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, Venetsanou KS, Iliodromitis EK, and Kremastinos DT. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol (in press).
62. Leibovitch ER. Hypertension 2008, refining our treatment. Geriatrics 63: 14-20, 2008.
63. Letsas KP, Sideris A, Efremidis M, Pappas LK, Gavrielatos G, Filippatos GS, and Kardaras F. Prevalence of paroxysmal atrial fibrillation in Brugada syndrome: A case series and a review of the literature. J Cardiovasc Med (Hagerstown) 8: 803-806, 2007.
64. Li S, Li X, Zheng H, Xie B, Bidasee KR, and Rozanski GJ. Pro-oxidant effect of transforming growth factor-β1 mediates contractile dysfunction in rat ventricular myocytes. Cardiovasc Res 77: 107-117, 2008.
65. Li X, Ma C, Dong J, Liu X, Long D, Tian Y, and Yu R. The fibrosis and atrial fibrillation: Is the transforming growth factor-β1 a candidate etiology of atrial fibrillation. Med Hypotheses 70: 317-319, 2008.
66. Lin CS and Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65: 1489-1508, 2008.
67. Lindholm LH, Dahlof B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, Snapinn S, and Wachtell K. Effect of losartan on sudden cardiac death in people with diabetes: Data from the LIFE study. Lancet 362: 619-620, 2003.
68. Liu H, Clancy C, Cormier J, and Kass R. Mutations in cardiac sodium channels: Clinical implications. Am J Pharmacogenom 3: 173-179, 2003.
69. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, and Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90: 2056-2069, 1994.
70. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, Cave AC, Marber M, Monaghan MJ, and Shah AM. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51: 319-325, 2008.
71. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, and Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291: 1720-1729, 2004.
72. McNally JS, Davis ME, Giddens DP, Saha A, Hwang J, Dikalov S, Jo H, and Harrison DG. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am J Physiol 285: H2290-H2297, 2003.
73. Meerson FZ, Belkina LM, Sazontova TG, Saltykova VA, and Arkhipenko Y. The role of lipid peroxidation in pathogenesis of arrhythmias and prevention of cardiac fibrillation with antioxidants. Basic Res Cardiol 82: 123-137, 1987.
74. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, and Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104: 174-180, 2001.
75. Munzel T, Hink U, Heitzer T, and Meinertz T. Role for NADPH/NADH oxidase in the modulation of vascular tone. Ann NY Acad Sci 874: 386-400, 1999.
76. Neil JR and Schiemann WP. Altered TAB1:I κB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-κB activation during breast cancer progression. Cancer Res 68: 1462-1470, 2008.
77. Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, and Dudley SC, Jr. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53: 1652-1657, 2007.
78. Nunez C, Cansino JR, Bethencourt F, Perez-Utrilla M, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, and Royuela M. TNF/IL-1/NIK/NF- κB transduction pathway: A comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology 53: 166-176, 2008.
79. Ohara K, Miyauchi Y, Ohara T, Fishbein MC, Zhou S, Lee MH, Mandel WJ, Chen PS, and Karagueuzian HS. Downregulation of immunodetectable atrial connexin40 in a canine model of chronic left ventricular myocardial infarction: implications to atrial fibrillation. J Cardiovasc Pharmacol Ther 7: 89-94, 2002.
80. Ohki R, Yamamoto K, Ueno S, Mano H, Misawa Y, Fuse K, Ikeda U, and Shimada K. Gene expression profiling of human atrial myocardium with atrial fibrillation by DNA microarray analysis. Int J Cardiol 102: 233-238, 2005.
81. Pagliaro P and Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 19: 77-87, 2005.
82. Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, and Lin CS. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett 581: 526-534, 2007.
83. Pinsky DJ, Patton S, Mesaros S, Brovkovych V, Kubaszewski E, Grunfeld S, and Malinski T. Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res 81: 372-379, 1997.
84. Polyakova V, Miyagawa S, Szalay Z, Risteli J, and Kostin S. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 12: 189-208, 2008.
85. Price MO, Atkinson SJ, Knaus UG, and Dinauer MC. Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent. J Biol Chem 277: 19220-19228, 2002.
86. Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA, and Lin A. Activation of NF-κ B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 98: 6668-6673, 2001.
87. Qi X, Li K, and Rouleau JL. Endocardial endothelium and myocardial performance in rats: Effects of changing extracellular calcium and phenylephrine. J Mol Cell Cardiol 28: 859-869, 1996.
88. Royuela M, Rodriguez-Berriguete G, Fraile B, and Paniagua R. TNF-α/IL-1/NF-κB transduction pathway in human cancer prostate. Histol Histopathol 23: 1279-1290, 2008.
89. Saas J, Haag J, Rueger D, Chubinskaya S, Sohler F, Zimmer R, Bartnik E, and Aigner T. IL-1β, but not BMP-7 leads to a dramatic change in the gene expression pattern of human adult articular chondrocytes-portraying the gene expression pattern in two donors. Cytokine 36: 90-99, 2006.
90. Sarfstein R, Gorzalczany Y, Mizrahi A, Berdichevsky Y, Molshanski-Mor S, Weinbaum C, Hirshberg M, Dagher MC, and Pick E. Dual role of Rac in the assembly of NADPH oxidase, tethering to the membrane and activation of p67phox: A study based on mutagenesis of p67phox-Rac1 chimeras. J Biol Chem 279: 16007-16016, 2004.
91. Sarkar D, Vallance P, and Harding SE. Nitric oxide: Not just a negative inotrope. Eur J Heart Fail 3: 527-534, 2001.
92. Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, and Miyahara K. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 45: 441-445, 2004.
93. Savelieva I and Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 5: 30-41, 2008.
94. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N, Mann DL, and Khoury DS. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol 292: H1561-H1567, 2007.
95. Shang LL and Dudley SC, Jr. Tandem promoters and developmentally regulated 5′- and 3′-mRNA untranslated regions of the mouse Scn5a cardiac sodium channel. J Biol Chem 280: 933-940, 2005.
96. Shang LL, Gao G, and Dudley SC, Jr. The tail of the cardiac sodium channel. Channels (Austin) 2: 161-162, 2008.
97. Shang LL, Pfahnl AE, Sanyal S, Jiao Z, Allen J, Banach K, Fahrenbach J, Weiss D, Taylor WR, Zafari AM, and Dudley SC, Jr. Human heart failure is associated with abnormal C-terminal splicing variants in the cardiac sodium channel. Circ Res 101: 1146-1154, 2007.
98. Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, and Dudley SC, Jr. NF-κB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol 294: C372-C379, 2008.
99. Torok B, Roth E, Mezey B, Temes G, Toth K, and Pollak Z. Promising reduction of ventricular fibrillation in experimentally induced heart infarction by antioxidant therapy. Basis Res Cardiol 82 Suppl 2: 347-353, 1987.
100. Tsai CT, Lai LP, Hwang JJ, Chen WP, Chiang FT, Hsu KL, Tseng CD, Tseng YZ, and Lin JL. Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation. J Hypertens 26: 570-582, 2008.
101. Tsai CT, Lai LP, Hwang JJ, Lin JL, and Chiang FT. Molecular genetics of atrial fibrillation. J Am Coll Cardiol 52: 241-250, 2008.
102. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, Hsu KL, Tseng CD, Liau CS, and Tseng YZ. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 109: 1640-1646, 2004.
103. van der Velden HMW, van der Zee L, Wijffels MC, van LC, Dorland R, Vos MA, Jongsma HJ, and Allessie MA. Atrial fibrillation in the goat induces changes in monophasic action potential and mRNA expression of ion channels involved in repolarization. J Cardiovasc Electrophysiol 11: 1262-1269, 2000.
104. Vaquero M, Calvo D, and Jalife J. Cardiac fibrillation: from ion channels to rotors in the human heart. Heart Rhythm 5: 872-879, 2008.
105. Vejlstrup NG, Bouloumie A, Boesgaard S, Andersen CB, Nielsen-Kudsk JE, Mortensen SA, Kent JD, Harrison DG, Busse R, and Aldershvile J. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure. J Mol Cell Cardiol 30: 1215-1223, 1998.
106. Verheule S, Sato T, Everett T, Engle SK, Otten D, Rubart-von der LM, Nakajima HO, Nakajima H, Field LJ, and Olgin JE. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ Res 94: 1458-1465, 2004.
107. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, and Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107: 2926-2931, 2003.
108. Walker MK, Vergely C, Lecour S, Abadie C, Maupoil V, and Rochette L. Vitamin E analogues reduce the incidence of ventricular fibrillations and scavenge free radicals. Fundam Clin Pharmacol 12: 164-172, 1998.
109. Wang CH, Hu DY, Tang CZ, Wu MY, Mei YQ, Zhao JG, and Qi HW. [Changes of interleukin-1b and tumor necrosis factor-α of right atrial appendages in patients with rheumatic valvular disease complicated with chronic atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi 33: 522-525, 2005.
110. Wellens HJ. Twenty-five years of insights into the mechanisms of supraventricular arrhythmias. J Cardiovasc Electrophysiol 14: 1020-1025, 2003.
111. Wyse DG. Therapeutic considerations in applying rate control therapy for atrial fibrillation. J Cardiovasc Pharmacol 52: 11-17, 2008.
112. Xiao HD, Fuchs S, Campbell DJ, Lewis W, Dudley SC, Jr., Kasi VS, Hoit BD, Keshelava G, Zhao H, Capecchi MR, and Bernstein KE. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165: 1019-1032, 2004.
113. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, Davis BB, Low R, Hammock BD, and Chiamvimonvat N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103: 18733-18738, 2006.
114. Yamashita T, Sekiguchi A, Iwasaki YK, Sagara K, Hatano S, Iinuma H, Aizawa T, and Fu LT. Cibenzoline attenuates upregulation of Kv1.5 channel gene expression by experimental paroxysmal atrial fibrillation. Int Heart J 46: 279-288, 2005.
115. Youn BS, Liu CC, Kim KK, Young JD, Kwon MH, and Kwon BS. Structure of the mouse pore-forming protein (perforin) gene: analysis of transcription initiation site, 5′ flanking sequence, and alternative splicing of 5′ untranslated regions. J Exp Med 173: 813-822, 1991.
116. Yue L, Melnyk P, Gaspo R, Wang Z, and Nattel S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res 84: 776-784, 1999.
117. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, and Daniel WG. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44: 215-222, 1999.
118. Zhang M, Kho AL, Anilkumar N, Chibber R, Pagano PJ, Shah AM, and Cave AC. Glycated proteins stimulate reactive oxygen species production in cardiac myocytes: involvement of Nox2 (gp91phox)-containing NADPH oxidase. Circulation 113: 1235-1243, 2006.
119. Zhou A, Ou AC, Cho A, Benz EJ, Jr., and Huang SC. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5′ splice site selection. Mol Cell Biol 28: 5924-5936, 2008.